Press Releases

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the U.S. Food and Drug Administration (FDA) has authorized an Investigational New Drug (IND) application to initiate a Phase 2b clincial trial of the mGluR5 inihibitor NOE-101 in trigeminal neuralgia (TN). The LibraTN trial is a multi-center, 24-week, prospective, double-blind, randomized-withdrawal, placebo-controlled study to evaluate the efficacy and safety o

Avicanna Inc. an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it has executed a non-binding term sheet with Tetra Bio-Pharma (“Tetra”) to assess entering into a strategic partnership comprising of three strategic pillars, including: The registration and commercialization of Tetra’s various prescriptio

On the occasion of World Epilepsy Day , Angelini Pharma, international Italian pharmaceutical company, is committed to provide patients and healthcare professionals with innovative solutions improving the care of patients with epilepsy. Epilepsy is a common neurological disorder that typically results in seizures of various types, with focal seizures being the most common.1 The essential treatment goal of epilepsy therapy is freedom from seizures.2 The global disease burde

Ascletis Pharma Inc.  today announces that it has submitted marketing authorization applications for ritonavir (100 mg film-coated tablet) in Germany, France, Ireland and United Kingdom through its agent in Europe. It is expected that more marketing authorization applications for ritonavir in certain other countries, including the ones in Europe, North America and Asian Pacific will soon be submitted. Ascletis has been in discussion with both domestic and international companie

Kintor Pharmaceutical Limited , a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the enrollment and dosing of first patient in China in its multi-regional phase III clinical trial (NCT04869228) of proxalutamide for the treatment of COVID-19 outpatients in the Third People's Hospital of Shenzhen in China on 10 February 2022. The phase III trial is a randomized, double-blind, placebo-controlled, multi-regiona

ProBioGen announces a multi-product commercial license agreement with AstraZeneca to use the GlymaxX technology. Following evaluation of the technology under a research license, AstraZeneca will now continue to use GlymaxX and will integrate the technology into their drug discovery. GlymaxX improves target cell killing orchestrated by natural killer cells, thereby enhances antibody-dependent cell-mediated cytotoxicity (ADCC). It is a universal, simple technology that allow

Recently, two companies that have been active in the field of Host Cell Protein (HCP) detection for many years have partnered up to offer their respective methods to biologics developers for optimal outcomes. While BioGenes specializes in the development of HCP ELISAs and related 2D gel analytics, Alphalyse is an expert in HCP coverage analysis by Liquid Chromatography (LC) - Mass Spectrometry (MS). HCPs stem from the production cell line used for biological product manufacturing. D

Sunovion Pharmaceuticals Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc.today announced that the first patient has been randomized in SEP380-301, a Phase 3 clinical study evaluating non-racemic amisulpride for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression). Non-racemic amisulpride is being jointly developed and commercialized as part of a collaboration between Sunovion, its parent company Sumitomo Dainippon Pharma an

MaaT Pharma , a French clinical-stage biotech  and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer and Skyepharma, a Contract Development and Manufacturing Organization (CDMO) specialized in formulating and manufacturing complex and controlled release drugs, today announced they have entered a partnership agreement to build, to date, France’s largest specialized cGMP manufacturing facility for ec

Morphocell Technologies Inc. announces the development of an innovative, scalable method for generating cells that may enable future cell therapies for liver diseases and improve the way these conditions are studied in the lab and how future medications for other illnesses are developed. Researchers discovered a high-yield method to produce high-quality liver cells (hepatoblasts and hepatocytes) from pluripotent stem cells. Robustly generated from unlimited source material, these ce